-
Trypsin-Responsive Nanomedicine for Acute Pancreatitis
2026-09-19
Wang and colleagues developed a mesoporous organosilica nanomedicine that combines pancreatic acinar-cell targeting with trypsin-triggered degradation and intracellular calcium chelation. In a mouse model of acute pancreatitis, the formulation reduced calcium overload, suppressed inflammatory and necrotic signaling, improved pancreatic enzyme profiles, and increased survival, although substantial translational questions remain.
-
PPT and ERα: From Biomarkers to Mechanism
2026-09-18
A translational framework for using PPT (Propyl Pyrazole Triol) to separate ERα biology from ERβ activity and test estrogen-linked mechanisms in female lung adenocarcinoma. The article connects biomarker-network evidence involving FOXM1 and ESR1 with practical validation strategies for oncology and hormone-receptor research.
-
CB-839 (Telaglenastat) Assay Workflows
2026-09-17
CB-839 (Telaglenastat) gives researchers a direct way to test GLS1-dependent glutaminolysis, complementing studies of PRMT5-driven metabolic rewiring in MYCN-amplified neuroblastoma. This workflow connects viability, glutamate depletion, isotope tracing, and autophagy readouts for more rigorous cancer metabolism research and preclinical cancer drug evaluation.
-
Fulvestrant: ER Degradation and Assay Design
2026-09-17
Fulvestrant (ICI 182,780) is more than an estrogen receptor blocker: it is a mechanistic probe for ERα degradation, MDM2 protein degradation, and pathway-dependent drug response. This guide connects breast cancer experiments with immune-cell evidence while defining practical assay boundaries.
-
0.4% Trypan Blue Solution: Practical QC Guide
2026-09-17
0.4% Trypan Blue Solution provides a direct method for cell viability measurement by distinguishing unstained viable cells from blue-stained dead or membrane-damaged cells during counting. It is intended for research workflows such as cell counting and cytotoxicity assays, but it should not be used for diagnostic, medical, or standalone mechanistic apoptosis analysis.
-
Regorafenib (BAY 73-4506) Research Guide
2026-09-16
Regorafenib, also called BAY 73-4506, is an oral multikinase inhibitor used to study angiogenesis, oncogenic signaling, and tumor progression. Its reported activity spans VEGFR, PDGFR, KIT, RET, RAF, and related pathways, while recent melanoma research connects activity to RRM2 and ERK/E2F3 signaling.
-
DHEA as a Stress-Response Research Tool
2026-09-15
Dehydroepiandrosterone (DHEA) is a context-dependent steroid research tool spanning neuroprotection and ovarian biology. This guide connects DHEA assay design with new evidence on oxidative stress, endoplasmic reticulum stress, and granulosa-cell apoptosis while defining critical interpretation limits.
-
PRMT5, Splicing, and Glutamine Vulnerability in Neuroblastom
2026-09-15
The reference study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-regulated RNA splicing, epitranscriptomic control, and glutamine metabolism. By combining transcriptomics, isotope tracing, molecular validation, and a genetically relevant mouse model, the authors connect spliceosomal disruption with reduced GLS protein and metabolic stress.
-
nor-NOHA Acetate: Cancer Assay Workflows
2026-09-14
Build reversible arginase-inhibition experiments around nor-NOHA acetate, from HepG2 apoptosis and invasion assays to endothelial and AML immunometabolic models. This workflow combines solvent discipline, orthogonal readouts, and explicit limits on cross-domain interpretation.
-
AG-120 (Ivosidenib) AML Research Workflows
2026-09-14
Build more informative IDH1-mutant AML assays with AG-120 (Ivosidenib), combining proximal 2-hydroxyglutarate reduction with differentiation and metabolic readouts. The workflow also translates CD44-driven metabolic rewiring into practical resistance and combination-testing experiments.
-
Cefotaxime for AMR Transmission Assays
2026-09-13
Cefotaxime can connect antimicrobial susceptibility phenotypes with plasmid localization, gene transfer, and strain relatedness. This article develops an evidence-calibrated assay framework inspired by a 2025 Enterobacter cloacae transmission study, while defining what Cefotaxime can—and cannot—demonstrate.
-
Covalent SARS-CoV-2 Mpro Binders from HCV Drugs
2026-09-12
The reference study combines crystallography, binding assays, and molecular docking to show that three clinically approved hepatitis C drugs and two additional drug-like compounds covalently engage the SARS-CoV-2 main protease catalytic residue Cys145. Its main contribution is a structural rationale for antiviral drug repurposing, while also showing why biochemical binding evidence must be followed by cellular, pharmacological, and clinical validation.
-
Pyridostatin TFA: G-Quadruplex Research Guide
2026-09-12
Pyridostatin TFA is a synthetic G-quadruplex stabilizer used to study telomere dysfunction, DNA secondary structure, and cancer cell growth. Product information reports preferential in vitro cytotoxicity toward HT1080 fibrosarcoma cells versus WI-38 fibroblasts, while recent research shows that RNA G-quadruplexes can also modulate TDP-43 condensation and toxicity.
-
Angiotensin 1/2 (1-6): From RAS to Translation
2026-09-11
Angiotensin 1/2 (1-6) is more than a short renin-angiotensin system fragment. Its defined sequence, vascular relevance, and emerging role in spike–AXL binding make it a useful probe for connecting cardiovascular, renal, and viral pathway research while preserving the discipline required for translational interpretation.
-
A-1210477 Workflow for MCL-1 Apoptosis
2026-09-11
A-1210477 is a selective MCL-1 inhibitor for distinguishing MCL-1-dependent survival from nonspecific cytotoxicity in cancer models. This practical workflow combines mitochondrial readouts, dependency controls, and navitoclax combination testing while clearly separating useful in vitro evidence from in vivo translation limits.